Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer.
Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer.
复制标题
患有乳腺癌的绝经后妇女的他莫昔芬使用、雌激素结合和血清脂质。
DOI：
--
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
D. Ingram
中科院分区：
文献类型：
--
作者：
D. Ingram
他莫昔芬被广泛用于乳腺癌的管理，包括在早期疾病的妇女中长期使用，以减少复发和死亡率。虽然非常无副作用，但人们担心它的抗雌激素活性可能会扩展到脂质代谢，从而导致冠心病的过早发展。在一项针对乳腺癌患者的研究中，服用他莫昔芬的患者往往胆固醇浓度较低（主要是低密度脂蛋白胆固醇），甘油三酯浓度升高。这些变化可能对冠心病有保护作用，表明他莫昔芬在脂质代谢方面具有雌激素作用而非抗雌激素作用。
Tamoxifen is widely used in the management of breast cancer, including long-term use in women with early disease to reduce recurrence and mortality. Although remarkably side-effect free, concern has been expressed that its anti-oestrogen activity may extend to lipid metabolism and so result in the premature development of coronary heart disease. In a study of breast cancer patients, those taking Tamoxifen tended to have lower cholesterol concentrations (predominantly low-density lipoprotein cholesterol) and raised triglyceride concentrations. These changes are likely to be protective for coronary heart disease, suggesting Tamoxifen has an oestrogenic rather than anti-oestrogenic effect as regards lipid metabolism.